QPPV.COM KNOWLEDGE ASSESSMENT

Valsartan: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Valsartan: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient taking valsartan and a loop diuretic develops diarrhoea, dizziness and a marked creatinine increase. Which follow-up approach is most informative?
Question 2 of 10 A patient taking a fixed-dose valsartan/amlodipine product reports ankle swelling. Which reporting approach is most appropriate?
Question 3 of 10 A patient with renal vascular disease develops a creatinine increase after starting valsartan. Which interpretation best reflects the article's discussion of renal risk?
Question 4 of 10 Which information set is most useful when investigating a suspected nitrosamine-related valsartan exposure?
Question 5 of 10 What is the most defensible interpretation of VALIANT for a patient following a myocardial infarction complicated by heart failure or left ventricular dysfunction?
Question 6 of 10 Which statement best describes the relationship between pharmacovigilance case processing and quality-defect management?
Question 7 of 10 A patient reports pregnancy while taking valsartan. Which response best reflects the safety implications described in the article?
Question 8 of 10 A patient has dizziness while taking valsartan, but there is no documented low blood pressure, syncope or fall. Which approach is most appropriate for the safety narrative?
Question 9 of 10 A pharmacy identifies that a patient received a recalled valsartan batch several months earlier, but no adverse event is reported. What is the most appropriate initial handling?
Question 10 of 10 Following a public recall announcement, spontaneous reports involving valsartan increase. Which conclusion is scientifically appropriate?

Select an answer to continue.

QPPV.com